No longer enrolling, in long-term follow up

Phase I High Risk or Steroid Refractory Acute Graft Versus Host Disease Clinical Trial

The Midwest Stem Cell Therapy Center is currently recruiting for a phase I study to evaluate the safety of umbilical cord-derived, ex-vivo cultured and expanded Wharton's Jelly Mesenchymal stem cells for the treatment of de novo high risk acute or steroid refractory acute graft versus host disease.

The objective of this study is to evaluate the safety of umbilical cord derived, ex-vivo cultured and expanded Wharton's Jelly Mesenchymal stem cells (MSCTC-0010) to treat de novo high risk (HR) aGVHD or steroid refractory (SR) aGVHD and to assess feasibility of rapid biomarker-based risk stratification.

To view the most up-to-date information about the study, visit ClinicalTrials.gov (NCT03158896).

Principal Investigator, Joseph McGuirk, D.O.

No longer enrolling, in long-term follow up

A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction (Pre-SERVE AMI), sponsored by Amorcyte.

Principal Investigator, Buddhadeb Dawn, M.D.

The primary objective of the study is to determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion using the resting total severity score (RTSS), measured by gated SPECT MPI at baseline and six months, in subjects with STEMI.

Single-center randomized double-blind placebo-controlled phase 2 proof of concept study to assess the efficacy and safety of ASCT01 in Patients with Critical Limb Ischemia, sponsored by Lifecells LLC.

Principal Investigator, Buddhadeb Dawn, M.D.

The primary objective of this trial is to compare the effects of treatment with ASCT01 with placebo in patients with critical limb ischemia who have exhausted all options for revascularization.

Phase II "ALLSTAR" clinical trial, sponsored by Capricor, Inc. (Capricor).

Principal Investigator, Buddhadeb Dawn, M.D.

In the "ALLSTAR" (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration) trial, the MSCTC and Capricor are investigating whether heart-derived adult stem cells directly infused into the area affected by a heart attack can repair heart muscle that is dead or has been damaged as a result of that heart attack. The infusion contains Capricor's proprietary off-the-shelf stem cell product, CAP-1002, derived from donor heart tissue.

A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

Principal Investigator, Paul Camarata, M.D.

The primary objective of this Phase II study is to determine the efficacy of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke. The study is conducted at approximately 65 sites in the United States.